BioSpace News Archive

Cerevel Therapeutics , a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Abraham N. Ceesay to the newly-created role of president, effective May 3, 2021. Mr. Ceesay brings nearly two decades of healthcare experience leading operations at a number of biopharmaceutical companies, serving most recently as chief executive officer at Tiburio Therapeutics

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, was invited to deliver a company presentation and participate in a panel at the 4 th Annual Neuroscience Innovation Forum for Business Development, Licensing and Investment, hosted by Sachs Associates and taking place from April 28-30, 2021

-- REMAP-CAP is led by experts in pandemic response and builds upon a worldwide clinical trial network evaluating treatments for COVID-19 Interim review of Imperial College London TRV027 study data supports transition to larger study

North America’s leading Thyroid Surgery Center has established the Suh Scarless Thyroid Surgery Center in Tampa Florida, to provide the best robotic thyroid surgery for scarless removal of thyroid cancers, thyroid goiters, and thyroid nodules.

Six Poster Presentations Will Include New Analyses on ARAZLO ® , DUOBRII ® and SILIQ ®

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, May 5 th at 11:30 a.m. Eastern Time to discuss its first quarter 2021 financial results and report on pipeline and business product

REGENXBIO Inc. (Nasdaq: RGNX) today announced that Curran M. Simpson , Chief Operations and Technology Officer, will present at the Chardan 5th Annual Genetic Medicines Manufacturing Summit on Tuesday, April 27, 2021 at 3:15 p.m. ET . The conference will be held in a virtual meeting format.

BioStable Science & Engineering, Inc. (“BioStable”) announced today the company has received CE Mark approval for the HAART 200 Aortic Annuloplasty Device for use during bicuspid aortic valve repair.

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced the appointment of Adrian Kilcoyne, MD, MBA, MPH, to the newly-created role of Chief Medical Officer, effective immediately

NEWS SUMMARY: Amol Chaubal named Waters Chief Financial Officer Jonathan Pratt named Senior Vice President of new Waters Division Jianqing Bennett named Senior Vice President of TA Instruments Division Mike Harrington, Senior Vice President of Global Markets, and Ian King, Senior Vice President of Global Products, to retire